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ABSTRACT 
Objective: This study aimed to determine the possibility of nanostructured lipid carriers (NLCs) as a bionic tear film by determining the surface 
activities of the developed NLCs and their interaction with human meibomian lipid films.  
Methods: NLCs with different types of solid lipids and surfactants were prepared by a high-pressure homogenizer. The particle size was 
determined by dynamic light scattering. The surface activities of the NLCs and NLCs mixed with meibomian lipids were measured using a Langmuir 
trough and the resulting surface pressure area (Π-A) profiles were compared. These lipid films were further analyzed using fluorescence 
microscopy and scanning electron microscopy (SEM).  
Results: The particle size of prepared NLCs varied from 38–280 nm based on types of solid lipid and surfactant. All NLCs were highly surface active as 
indicated by their maximum surface pressure (Πmax
Conclusion: NLCs are surface active and can integrate with meibomian lipid films formed stable films. The type of interaction can be tailored by 
altering the solid lipids used in the formulation of the NLCs which could provide the means to develop efficient formulations for targeting dry eye 
disease related to a non-functional tear film lipid layer. 
). The Π-A profiles of meibum seeded with NLCs showed higher surface pressure than meibum alone 
and the shape of profiles were dominated by the meibomian lipids. These findings were in agreement with fluorescence and SEM micrographs, which 
revealed that the NLCs could adsorb and integrate to the meibomian lipid films as well as diffuse from the subphase to the lipid films.  
Keywords: Tear film lipid layer (TFLL), Meibomian lipid films, Nanostructured lipid carriers (NLCs), Surface activity, Langmuir trough 




A mainly aqueous tear film covers the exposed ocular surface. For it 
to spread across the surface of the eye and form a stable thin film, 
it's surface tension at the air interface has to be lowered, otherwise, 
it would form tiny beads across the ocular surface. The tear film lipid 
layer (TFLL) reduces the surface tension of the tear film and 
therefore plays a major role in the spreading of the tear film [1]. The 
major component of the TFLL is meibum, a lipid secretion from 
holocrine glands in the eyelid [2]. The lipids in meibum are mainly 
hydrophobic wax and cholesterol esters with some triglycerides [3-
5]. Meibum also contains a small proportion of amphipathic lipids, 
particularly (O-acyl) omega hydroxy fatty acids, which act as 
surfactants. The exact structure of the TFLL is unknown because 
once meibum is secreted onto the ocular surface; it has the 
opportunity to interact with components of the aqueous layer that 
include mucins, other proteins, and lipids from other sources than 
meibum. Through these interactions, it self-assembles so that a 
normal tear film is resistant to evaporative loss [6]. 
It has been hypothesized that abnormal secretion of meibum or 
changes in its composition can cause tear film instability leading to 
dry eye disease (DED) [6, 7]. In general, artificial tear drops are used 
to give symptomatic relief from DED [8]. These drops are designed 
to target the TFLL or to provide a viscous aqueous substitute. 
However, they are washed out over time and hence require frequent 
instillation. This puts a burden on the patient and diminishes patient 
compliance. Accordingly, there is unmet need to enhance the 
artificial tear drops with agents that can provide sustained efficacy 
against signs and symptoms of DED. 
Nanostructured lipid carriers (NLCs) could be a solution to the 
problem of the short residence time of topical eye drops for DED 
[9]. In particular, the NLCs made from lipid assemblages have been 
shown to have strong mucoadhesiveness to corneal epithelium 
[10-12]. This means that they have a higher dwell time in the eye 
and hence could release its lipids through disintegration over a 
much longer period. This would markedly decrease the application 
frequency of a lipid-based eye drop. Ideally, these NLCs would 
ideally bind to the glycocalyx coating the surface of the corneal 
epithelium, and then slowly release their lipid contents into the tear 
film. These released lipids would then adsorb and penetrate the 
TFLL to improve the stability of TFLL (fig. 1). Furthermore, a release 
of other drugs incorporated into the NLCs is also possible. For this to 
happen, the NLCs formulated as an eye drop would first need to pass 
through the tear film and hence have the opportunity to interact 
with the TFLL. Therefore, this study focused on determining if the 
NLCs were able to interact directly with the TFLL. To study this 
potential interaction in more detail, meibomian lipid films were 
formed by spreading meibomian lipids on an aqueous buffer in a 
Langmuir trough [13-15]. This was used as a simple emulation of the 
TFLL [16, 17]. NLCs were then added to the subphase or mixed with 
the meibomian lipids, and their effect on the meibomian lipid films 
was examined. 
MATERIALS AND METHODS 
Materials 
Gelucire 44/14 (lauryl macrogol-32 glyceride), Gelucire 43/01 (hard 
fat), and Compritol 888 ATO (glyceryl behenate) were kindly gifted by 
Gattefossé (Cedex, France). LexolGT865 (medium chain triglyceride), 
cetyl palmitate, and squalene were purchased from Namsiang trading 
(Bangkok, Thailand). Tween 80 was purchased from Ajex Finechem 
(Sydney, Australia). Emulmetik 900 was purchased from Lucas Meyer 
(Ludwigshafen, Germany). Amicon Ultra 10K centrifugal filter was 
purchased from Merck Millipore (Massachusetts, USA).  
Nile red was purchased from Sigma Aldrich (Massachusetts, USA). NBD-
DPPC (1-plamitoyl-2-[12-[(7-nitro-2-1,3-benzoxadiazol-4-yl) amino-
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dodecanoyl]-sn-glycero-3-phosphatidylcholine) was obtained from 
Avanti Polar Lipids Inc. (Tullamarine, USA). Chloroform (HPLC grade) 
used for dissolving lipids was purchased from LabScan (NSW, 
Australia). There was no residual surface activity associated with this 
solvent. Ion exchange purified water (Milli-Q; Millipore, Billerica, MA) 
with a resistance of 18.2 MΩ was used in all experiments. An artificial 
tear (AT) buffer that emulates ion concentrations in human tears was 
prepared (6.6 g/l NaCl, 1.7 g/l KCl, 1.4 g/l NaHCO3, 0.15 g/l CaCl2, 0.1 
g/l NaH2PO4
  
, 4.18 g/l MOPS, pH 7.4) and used as the subphase in the 
surface pressure experiments described below. 
 
Fig. 1: Proposed mechanisms of NLCs after being instilled onto the ocular surface. The NLCs pass through the tear film and may be 
endocytosed by epithelial cells (A), or bind to the glycocalyx of the epithelium and slowly release the loaded drug into the corneal 
epithelium. The NLCs may bind directly to the tear film lipid layer (TFLL) or disintegrate to release their lipids and surfactants, which 
then merge with TFLL (D) to enhance the tear film stability 
 
Preparation of NLCs 
NLCs were prepared by a high-pressure homogenization (HPH) 
technique with a variation of solid lipid and surfactant (table 1). 
Briefly, the lipid phase contained 2% (w/w) squalene, 2% (w/w) 
Emulmetik 900, 2% (w/w) Lexol GT865, and 3% (w/w) solid lipid 
(water comprised the remaining mass of the final NLCs). It was heated 
to 85 °C to melt the lipids. The aqueous phase, consisting of 5% (w/w) 
surfactant dispersed in distilled water, was slowly added to the oil 
phase at the same temperature while gently stirring with a glass rod. 
This primary emulsion was then stirred at 5000 rpm using a high-
speed homogenizer (IKA®
The mean particle size and polydispersity index (PI) of NLCs were 
determined by dynamic light scattering (DLS) with a 
ZetaPALS
-T18, Staufen, Germany) for 1 min and then 
subjected to a high-pressure homogenizer (Microfluidics M-110P, 
Massachusetts, USA) applying 5 cycles at 1500 bar. The resulting hot 
o/w microemulsion was rapidly cooled to 25 °C, re-solidifying the lipid 
and forming the NLCs. The resulting NLCs were washed twice with 
0.9% NaCl solution in purified water using an ultrafiltration system 
(Amicon 8400, Massachusetts, USA) fitted with a molecular weight cut 
off 100 kDa membrane to remove the excess starting components. 
® analyzer (Brookhaven 90Plus, New York, USA). The zeta 
potential of NLCs was determined by measuring the particle 
electrophoretic mobility using ZetaPAL®
Surface pressure-area (Π-A) measurements of NLCs  
analyzer. 
The surface activity at an air-water interface of different 
formulations of NLCs was assessed by measuring changes to 
pressure-area (Π-A) isocycles in a double barrier Langmuir trough 
(NIMA 102M, Coventry, UK). NLCs and their components were 
spread onto the surface of artificial tear buffer at 35 °C in a double 
barrier Langmuir trough, isocycles performed, and then the trough 
was cooled to 20 °C and further isocyles made. The samples were 
deposited by touching micro-drops of the solution to the surface of 
the subphase. The quantity of lipids applied to the surface was 
chosen so that the initial Π was lower than 1mN/m. The surface was 
compressed and expanded at a rate of 15 cm2/min with using a 
maximum surface area of 79 cm2 and a minimum surface area of 16 
cm2
The interaction of human meibomian lipid with optimized NLCs 
. A Whilhelmy balance with Whatman filter paper type No.1 was 
used to record surface pressure during isocycles. 
Meibomian lipids were collected using a metal spatula [18] from one 
of the authors, a 62-year-old male with no known ocular pathology. 
Samples from different collection dates (all within a week) were 
dissolved in chloroform and pooled, and this single pooled sample was 
used for all experiments. The sample was dried under nitrogen gas and 
reconstituted to 1 mg/ml in chloroform and stored-20 °C. 
For microscopic analysis, the meibomian lipid films were doped with 
fluorescent marker 1% (w/w) NBD-DPPC, and 20 µl of the mixture 
was spread at the air-buffer interface between two movable barriers 
in the Langmuir trough to form the meibomian lipid films. After 10 
min, to allow chloroform evaporation, Π-A isocycles were carried out 
at 35 °C as described above until equilibrium was reached (about 10 
isocycles). The NLCs dispersions (3 µl) were applied to the surface of 
the meibomian lipid film and further Π-A isocycles recorded. After 
10 isocycles, the temperature was decreased to 20 °C and further 
isocycles recorded.  
The surface film was observed microscopically at a 400x 
magnification using a Leica epifluorescence microscope. The 
microscope was equipped with an excitation band to pass filter of 
450-490 nm, a dichroic mirror with a reflection short pass of 510 nm 
and a barrier filter with a line pass of 515 nm for labeled lipid which 
fluoresced green. The filters could be swapped using a manual slide. 
Digital images were recorded using an Andor Ixon back-illuminated 
DV887ECS-BV camera at a shutter speed of 10-2 
The penetration of NLCs to the human meibomian lipid film  
s or less.  
Nile red (0.0005% w/v), a lipophilic fluorescent dye, was added to the 
lipid phase of some NLCs formulations during the preparation process 
to give fluorescence tagged NR-NLCs. NBD-DPPC doped meibomian 
lipid films were prepared at 20 °C as described above. After the 
equilibrium of these films were reached (10 isocycles), the barriers of 
the trough were moved so that the surface area was 30 cm2. Six 
microliters of NR-NLCs were injected into the subphase outside of the 
barrier, and Π was monitored over time with the area fixed at 30 cm2
Again, the surface films were observed under a Leica epifluorescence 
microscope as described above. In case of NR-NLCs, an excitation 
bandpass filter of 535-550 nm, dichroic mirror with a reflection 
short pass of 590 nm and a barrier filter with a bandpass of 610-675 
nm were used. The filters could be swapped using a manual slide. 
Digital images were recorded using an Andor Ixon back-illuminated 
DV887ECS-BV camera at a shutter speed of 10
. 
When there was no further change in Π observed over time, a series of 
isocycles were performed, and Π-A profiles were recorded. 
-2 
Scanning electron microscopy (SEM, JSM-7001F, JEOL, Tokyo, Japan) 
was used to visualize the surface morphology of NR-NLCs at the air 
interface. A silicon wafer was gently touched to the interface 
s or less. 
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avoiding dipping it into the subphase. The sample was allowed to 
air-dry at room temperature and sputter-coated with gold. Then 
photomicrographs were taken at an acceleration voltage of 15 kV at 
a magnification of 10,000X. 
RESULTS AND DISCUSSION 
NLCs formulations 
In this study, NLCs were successfully prepared by a high-pressure 
homogenization technique with different types of solid lipid and 
surfactant. The physicochemical properties of different NLCs 
formulations are summarized in table 1. The particle sizes were 
various from 38–280 nm based on types of solid lipid and surfactant. 
As previously reported, the number of the fatty acid side chain on 
solid lipid and surfactant had a significant effect on the particle size 
of NLCs [19].  
With regard to the different solid lipids, NLC1, NLC4, and NLC7, 
prepared with Compritol 888 ATO (fatty acid side chains, C22), 
showed larger particle sizes of 280±9, 229±11, and 154±5 nm, 
respectively. Whereas preparing with Gelucire® 43/01 ((fatty acid 
side chains, C18); NLC2, NLC5, and NLC8) and cetyl palmitate ((fatty 
acid side chains, C16); NLC3, NLC6, and NLC9), the particle size was 
substantially smaller averaging approximately 40 nm. Indeed, NLC1 
prepared with tween 80 (fatty acid side chains, C18) as a surfactant, 
demonstrated a larger particle size compared to NLC4 prepared 
with of mix of tween 80 and span 20 (fatty acid side chains, C18 and 
C12) and NLC7 prepared with Gelucire 44/14 (fatty acid side chains, 
C12
 
). The larger size can be attributed to the solid lipid and 
surfactant with long fatty acid side chain [20]. However, in the case 
of NLCs prepared with Gelucire 43/01 and cetyl palmitate, the use 
of different surfactants appeared to have no influence on their 
particle size (table 1). Also, all NLCs formulations exhibited a high 
zeta potential of-30 mV, which is important for long-term physical 
stability. The negative charge is most likely due to the presence of 
slightly ionized fatty acids from triglycerides, including Gelucire 
44/14, Compritol 888 ATO, cetyl palmitate, and LexolGT865, on the 
particle surface [21]. 
Table 1: The components and physicochemical properties of NLCs 
Formula Solid lipid Surfactant PS (nm)±SD PI±SD ZP(mV)±SD 
NLC1 Compritol 888 ATO tween 80 280±9 0.22±0.06 -33±3 
NLC2 Gelucire 43/01 tween 80 35±6 0.27±0.02 -29±4 
NLC3 cetyl palmitate tween 80 39±5 0.25±0.00 -30±2 
NLC4 Compritol 888 ATO tween 80: span 20 229±11 0.25±0.03 -29±3 
NLC5 Gelucire 43/01 tween 80: span 20 44±4 0.22±0.04 -27±5 
NLC6 cetyl palmitate tween 80: span 20 38±3 0.25±0.03 -25±3 
NLC7 Compritol 888 ATO Gelucire 44/14 154±5 0.27±0.01 -31±4 
NLC8 Gelucire 43/01 Gelucire 44/14 38±3 0.28±0.04 -27±1 
NLC9 cetyl palmitate Gelucire 44/14 35±6 0.23±0.02 -26±3  
SD: standard deviation for n=3, PS = particle size, PI = polydispersity index, ZP = zeta potential 
 
The surface activity of NLCs formulations 
An appropriate model for studying the behavior of NLCs at air/water 
interface is to monitor their ability to spread using a Langmuir 
trough and measuring changes in Π. This has been used previously 
to study films of pure lipid and models of the TFLL [13-15]. Typically 
experiments are carried out at both 20 °C and at the temperature of 
the ocular surface at ~35 °C. The lower temperature is used because 
it is a temperature commonly used by physical chemists who use 
these techniques and hence allows the results to be compared more 
broadly with current literature. It should also be noted that molar 
quantities of nanoparticles could not be determined because there 
was a small variance in the size of the particles. The amounts chosen 
to apply to the trough were such that take-off of the Π-A isotherms 
(having a measurable pressure) was just below the maximum 




Fig. 2: Π-A curves comparing films of NLCs prepared with A) Compritol 888 ATO, B) Gelucire 43/01, and C) cetyl palmitate as solid lipid 
and tween 80 as a surfactant when spread at 35 °C and then decreased to 20 °C. D) A direct comparison between the first isocycles of the 
three different NLCs
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The Π-A isocycles of NLCs prepared with various solid lipid types as 
well as the effects of different surfactants are shown in fig. 2-4. All 
NLCs formulations showed high surface activity requiring only ~100 
ng of material to be applied to the surface. Surface activity was slightly 
higher at 35 °C versus 20 °C, which is to be expected based on the 
enhanced movement of the NLCs at higher temperatures. There was 
little change in the Π-A curves over multiple isocycles except for a 
slight decrease in Π , which would most likely indicate a reorganization 
of the NLCs on the surface. Films of NLC2 at 35 °C were an exception 
and showed a slight increase in Πmax
 
 over multiple isocycles (fig. 2B). 
 
Fig. 3: Π-A curves comparing films of NLCs prepared with A) Compritol 888 ATO, B) Gelucire 43/01, and C) cetyl palmitate as solid lipid 
and tween 80: span 20 as a surfactant when spread at 35 °C and then decreased to 20 °C. D) A direct comparison between the first 
isocycles of the three different NLCs 
 
 
Fig. 4: Π-A curves comparing films of NLCs prepared with A) Compritol 888 ATO, B) Gelucire 43/01, and C) cetyl palmitate as solid lipid 
and Gelucire 44/14 as a surfactant when spread at 35 °C and then decreased to 20 °C. D) A direct comparison between the first isocycles of 
the three different NLCs 
 
There was no collapse of any of the films due to high surface pressures, 
and so it is most likely that the small changes to take-off area and Πmax
In general, the structure of NLCs particles is composed of the lipid 
phase matrix which is covered by the surfactant. To ensure that the 
Π-A profiles of the NLCs were not due to the surface activity of 
unincorporated starting products, the Π-A profiles of the individual 
components used to form the NLCs were examined (Supplementary 
 
were due to changes in packing of the NLCs during the course of 
multiple isocycles. For NLCs that used Compritol 888 ATO as their 
solid lipid (NLC1, 4, and 7), slightly more sample had to be applied to 
the surface to achieve a targeted take-off area comparable to the other 
NLCs preparations. The reason for this is unclear, but it could be 
related to the size of the particles because these NLCs were much 
larger than the others (NLC2, 3, 5, 6, 8, and 9 having similar sizes ~37 
nm and NLC1 ~280 nm; NLC4 ~230 nm, and NLC7 ~150 nm).  
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fig. 1-3). The Π-A profiles of the individual components of NLCs 
required larger amounts to be applied to the surface and showed 
unique patterns characteristic to the component and was starkly 
different to the Π-A profiles of NLCs, which were made of these 
components. This confirms that the surface activity observed for the 
NLCs are not caused by free surface-active components, that had not 
been not removed during purification of the NLCs, but rather by the 
NLC themselves.  
The interaction of human meibomian lipid with optimized NLCs 
To study the interaction of meibum with NLCs, only NLCs prepared 
with tween 80 as the surfactant component was used (NLC 1, 2, 3, 
see table 1). The surface activity of meibomian lipid films has been 
well documented [16, 17] and commonly, isocycles of meibum 
spread on a Langmuir trough are examined [22]. In this study, 
sample Π-A curves of meibomian lipid films doped with 1% (w/w) 
NBD-DPPC (a fluorescent marker) before adding the NLCs at 35 °C 
and 20 °C are shown in fig. 5. The effects of NLCs (NLC1, NLC2, and 
NLC3) applied to fluoromeibomian lipid films are shown in fig. 6. 
The Π-A profiles of fluoromeibomian lipid films seeded with NLCs 
showed an increase in Πmax and the shape of the Π-A profiles were 
similar to those of meibomian lipid films alone and hence dominated 
by the meibomian lipids. Furthermore, the meibomian films mixed 
with NLCs did not collapse at the smallest surface areas even though 
they had more lipids applied to the surface (data not shown). This 
clearly indicated that the NLCs were contributing to the surface 
activity of the film and were most likely at the surface. There was a 
slight decrease in Π over multiple isocycles, and Πmax
 
 decreased 
over time at 35 °C, which was not observed with pure meibomian 
films. This could indicate some reorganisation of the NLCs at the 
surface or that some NLCs might be moving off the surface. There 
were some slight differences in the Π-A isocycle curves between the 
different NLCs mixed with meibum. Most notable was a slight phase 
shift (flattening of the profile) for the NLC2 seeded film at 35 °C. 
 
Fig. 5: Typical Π-A curves of A) Fluoromeibum at 35 °C and B) 
Fluoromeibum at 20 °C before adding the NLCs. Note that at the 
lower temperature Πmax
 
 was much higher and hysteresis greater 
 
Fig. 6: Π-A curves comparing films of meibomian lipids mixed with A) NLC1, B) NLC2, and C) NLC3 when spread at 35 °C (red line; 1st 




Fig. 7: Micrographs comparing the appearances of meibomian lipids mixed with A) NLC1, B) NLC2, and C) NLC3 during 1st and 
10thisocycles at 20 °C, respectively. The surface pressure during compression of the film and the isocycle is given, e. g. 8 iso 1 means that 
the pressure was 8 mN/m during compression in isocycle 1 
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These data indicated that the NLCs are surface active and interact with 
or are at least incorporated into meibomian lipid films. This ability of the 
NLC to interact with meibomian lipids has to be taken into account 
when using those NLCs as a potential vehicle for the delivery of drugs to 
the ocular surface. It also opens the possibility of designing NLCs to treat 
deficiencies in the tear film lipid layer in some forms of dry eye disease. 
Fluorescence microscopy was then used to investigate the 
distribution of the NLCs in the meibomian films (fig. 7). The films 
observed at 35 °C were too fluid and their fast changes did not allow 
photography of them. Thus only data for the film at 20 °C are 
reported. Brightly fluorescent regions in the films indicate regions 
rich in meibomian lipids and darker regions indicate areas depleted 
in meibomian lipids, and hence probably more abundant in NLCs. 
In general terms, the mixed films with the different NLCs gave 
different appearances, which means that the different NLCs 
interacted with the meibomian lipids differently. Since each of the 
different NLCs were prepared with the same surfactant, the 
difference must be attributed to other characteristics of the NLC, e. g. 
the effect of the solid lipid component, of their sizes or surface 
charges. Most notable was that NLC2 seemed to disperse within the 
film but not evenly mix with the film irrespective of the surface 
pressure or the number of isocylces. Similarly, NLC1 also did not mix 
evenly with the meibomian lipids, but different to NLC2 tended to 
remain in specific regions rather than dispersed throughout the film. 
This distribution pattern remained stable throughout many 
isocycles. At higher pressures, the darker zones, indicating 
meibomian lipid depletion, disappeared. This is likely to be due to 
NLC1 being forced off the surface, which also would explain the 
inflection at higher pressures in the Π-A isocycle curves (fig. 7). 
NLC3 seemed to mix more evenly with the meibomian lipids, at least 
in part, giving relatively even gray areas to the film when compared 
to NLC1 or NLC2. In the 1st
The penetration of NLCs to human meibomian lipid film 
isocyle bright fluorescing zones were 
visible suggesting that initially, NLC3 did not mix well with the 
meibomian lipids. However, within the next and the following 
isocycles the resulting film displayed an even appearance. 
It is anticipated that pharmaceutical formulations of NLCs would be 
applied to the ocular surface as aqueous-based drops and therefore 
in addition to interacting directly with the tear film lipid layer 
(simulated above), some NLCs could become incorporated in the 
aqueous component of the tear film and therefore, in theory, would 
have to diffuse to the TFLL in order to interact with it. This was 
tested by evaluating the penetration of NLCs from the subphase into 
a meibomian lipid film. Such penetration by NLCs from the 
subphase is indicated by an increase in Π over time of a meibomian 
lipid film kept at a fixed area. Following injection of NLCs into the 
subphase outside the barriers, Π slowly increased over time and 
then stabilised (fig. 8). After there was no further change in Π, a 
series of isocycles at 20 °C were performed and Π-A profiles were 
recorded. The Π-A profile showed similar characteristics to a pure 
meibomian lipid film. In addition, after the NLCs penetrated to the 
meibomian lipids film, there was greater surface activity (higher 
Πmax
  
) than that of the meibomian lipid film alone. This was further 
evidence that the NLCs had integrated into the meibomian lipid 
layer. In this case, the Nile red tagged NLCs was used and the 
meibomian lipids were seeded with a green fluorescing lipid (NBD-
DPPC). By swapping filters, the distribution of the NLCs in the films 
could be seen (fig. 9). The micrographs showed that there were 
regions of clumping of the fluorophores and this clumping increased 
with the number of isocycles. Both fluorophores showed the same 
pattern rather than complementary patterns indicating that there 
was mixing of the meibomian lipids, or at least of the fluorophores 
the meibum was doped with, with the Nile red NLCs whereas other 
areas of the film were depleted of those fluorophores (fig. 9). 
 
Fig. 8: Π-time curve of a fluoromeibum film with Π ini
 
 set to 20 mN/m at 20 °C, a further 6 µl of NR-NLCs added to the subphase (arrow), 
showed that NR-NLCs was able to still penetrate the film 
 
Fig. 9: Π-A curves of NR-NLCs penetrated to predeposited meibomian lipids at 20 °C (red line). The 10thisocycles of Fluoromeibum alone 
at 20 °C are also shown (black line). Micrographs of the appearances of meibomian lipids mixed with NR-NLCs during 1, 3, and 4 isocycles 
are represented. The curve with NR-NLCs is shifted to the right by the barriers being closed to 30 cm2 
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To determine if NLCs had reached the surface and had interacted 
with the meibomian lipid film, rather than possible breakdown 
products from the NLCs, samples of the film were collected using a 
silicon wafer. To allow space on the trough to collect the sample, the 
barriers were compressed to 30 cm2rather than the maximal normal 
15 cm2
 
. These were not true Blodgett films as the wafer was not 
placed in the subphase, but rather those films were collected from 
the air/lipid interface. This was to minimise the possibility of any 
particles being deposited on the wafer were indeed collected from 
the subphase rather than the surface. Scanning electron microscopy 
of these wafers showed that the NLCs had integrated into the 
meibomian lipid film (fig. 10). 
 
Fig. 10: SEM micrograph of NR-NLCs penetrated to fluoromeibum at 20 °C. Scale indicated by the white line at the bottom of the 
micrograph represents 1 µm 
 
CONCLUSION 
In summary, NLCs designed to attach to the ocular surface for the 
delivery of their drugs can also interact with meibomian lipid films 
both directly and by diffusing from the subphase. It is therefore 
likely that in vivo, NLCs applied in eye drop formulations to the 
ocular surface will also in part integrate into the lipid layer of the 
tear film. Therefore, the development of these types of nanoparticles 
for drug delivery must take this into account because disruption of 
the tear film lipid layer could lead to signs and symptoms of dry eye 
disease. On the other hand, as shown in this study, different types of 
NLCs interact with meibomian lipid films differently, and so it 
theoretically would be possible to tailor the NLCs to bind strongly to 
the ocular surface and at the same time have minimum effect on the 
lipid layer or even improve the performance of the lipid layer.  
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